NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy
Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival
OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent
Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study
First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors
Telatinib Demonstrates Positive Results in First-Line Treatment
Barret’s Less of a Risk Factor For Cancer of the Esophagus
New Abiraterone Acetate Results Show Greater Benefit Than Before
MGMT Gene Can Determine Disease Aggressiveness
Phase III Study: Lymphoseek Superior to Vital Blue Dye
Intensity Modulated Therapy Safer Than Three-Dimensional Radiation
Smokers Quitlines Found Effective Regardless of Recruitment Method
Study: Vismodegib Effective Where Surgery is Inappropriate
NCI-Approved Clinical Trials For The Month of June
FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”
FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- An opportunity for Trump: Position U.S. cancer science to lead the world
